Robaxin

(Methocarbamol) - Schwarz

OTHER BRAND NAMES
Robaxin Injection (Baxter), Robaxin-750 (Schwarz)

THERAPEUTIC CLASS
Muscular analgesic (central-acting)

DEA CLASS
RX

INDICATIONS
Adjunct for relief of acute, painful musculoskeletal conditions.

ADULT DOSAGE
Adults: (PO) Initial: (500mg tab) 1500mg qid for 2-3 days. Maint: 1000mg qid. Initial: (750mg tab) 1500mg qid for 2-3 days. Maint: 750mg q4h or 1500mg tid. Max: 6g/day for 2-3 days; 8g/day if severe. (Inj) Moderate Symptoms: 10mL IV/IM. IV Max Rate: 3mL undiluted drug/min. IM Max: 5mL into each gluteal region. Severe/Postop Condition: Max: 20-30mL/day up to 3 consecutive days. If feasible, continue with PO. Tetanus: 10-20mL up to 30mL. May repeat q6h until NG tube can be inserted. Continue with crushed tabs. Max: 24g/day PO.

PEDIATRIC DOSAGE
Pediatrics: Tetanus: Initial: 15mg/kg or 500mg/m^2. Repeat q6h prn. Max: 1.8g/m^2 for 3 consecutive days. Administer by injection into tubing or IV infusion.

HOW SUPPLIED
Inj: 100mg/mL [10mL]; Tab: 500mg, 750mg

CONTRAINDICATIONS
(Inj) Renal pathology with injection due to propylene glycol content.

WARNINGS/PRECAUTIONS
May impair mental/physical abilities. May cause color interference in certain screening tests for 5-hydroxy-indoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA). Caution in epilepsy with the injection. Injection rate should not exceed 3mL/min. Avoid extravasation with injection. Avoid use of injection particularly during early pregnancy.

ADVERSE REACTIONS
Lightheadedness, dizziness, drowsiness, nausea, urticaria, pruritus, rash, conjunctivitis, nasal congestion, blurred vision, headache, fever, seizures, syncope, flushing.

DRUG INTERACTIONS
Additive adverse effects with alcohol and other CNS depressants. May inhibit effect of pyridostigmine; caution in patients with myasthenia gravis receiving anticholinergics.

PREGNANCY
Category C, caution in nursing.

MECHANISM OF ACTION
Carbamate derivative of guaifenesin; not established, suspected to have CNS depressant with sedative and musculoskeletal relaxant properties.

PHARMACOKINETICS
Distribution: Plasma protein binding (46-50%). Found in breast milk. **Metabolism:** Via dealkylation, hydroxylation, and conjugation pathways. **Elimination:** Urine; $T_{1/2}$=1-2 hrs.

ASSESSMENT
Assess for renal/hepatic impairment, myasthenia gravis, seizures, pregnancy/nursing status, alcohol intake, and drug interactions.

MONITORING
Monitor for congenital and fetal abnormalities if taken during pregnancy, for color interference in certain screening tests for 5-HIAA using

nitrosonaphthol reagent and in screening tests for urinary VMA using Gitlow method.

PATIENT COUNSELING

Instruct to use caution while performing hazardous tasks (operating machinery/driving). Warn to avoid alcohol or other CNS depressants. Instruct to notify physician if pregnant/nursing or if planning to become pregnant.

ADMINISTRATION/STORAGE

Administration: Oral route, IV infusion, and IM; careful supervision of dose and rate of injection. **Storage:** 20-25°C (68-77°F), in tight container; excursions permitted to 15-30°C (59-86°F).